logo

EDIT

Editas Medicine·NASDAQ
--
--(--)
--
--(--)
6.55 / 10
Outperform

EDIT's fundamental score of 6.5/10 reflects strong PB-ROE (0.3140, Group 1), Asset-MV (-0.5007, Group 4), and Gross profit margin (100%, Group 4). However, Current assets turnover (0.0677, Group 1) and Fixed assets turnover (0.4579, Group 1) lag, pulling the overall metric down. These mixed signals result in an 'Outperform' fundamental rating, indicating decent intrinsic quality but room for operational improvement.

Fundamental(6.55)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-1.87
Score1/3
Weight8.23%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight7.23%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight16.53%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight12.32%
1M Return7.79%
PB-ROE
Value0.31
Score3/3
Weight19.34%
1M Return11.47%
Current assets turnover ratio
Value0.07
Score0/3
Weight-2.25%
1M Return-1.88%
Fixed assets turnover ratio
Value0.46
Score1/3
Weight-1.95%
1M Return-1.64%
Asset-MV
Value-0.50
Score3/3
Weight28.59%
1M Return14.99%
Cash-MV
Value-0.07
Score2/3
Weight12.33%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.36%
1M Return-0.30%
Is EDIT undervalued or overvalued?
  • EDIT scores 6.55/10 on fundamentals and holds a Discounted valuation at present. Backed by its -209.09% ROE, -430.84% net margin, -0.75 P/E ratio, 13.21 P/B ratio, and 7.48% earnings growth, these metrics solidify its Outperform investment rating.